tiprankstipranks
Fulcrum Therapeutics downgraded at Morgan Stanley on clinical hold uncertainty
The Fly

Fulcrum Therapeutics downgraded at Morgan Stanley on clinical hold uncertainty

Morgan Stanley analyst Matthew Harrison downgraded Fulcrum Therapeutics to Equal Weight from Overweight with a price target of $8, down from $27, as the firm sees significant uncertainty on the path to clinical hold resolution for FTX-6058. The firm believes the average clinical hold takes about 12 months to rectify and while it admits "there is clearly precedent for holds to be lifted sooner," it doesn’t expect management to be in a position to have clarity until mid-year and it also cites a lack of other near-term catalysts.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on FULC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles